BIOSIMILAR DRUGS
TODAY'S HEADLINES
Surprisingly, Medicare beneficiaries are likely to pay much more for biosimilars in the future than the referenced brand medication, a new report says. Find out why |
|
While FDA's new approval of Inflectra, a biosimilar to Remicade for rheumatoid arthritis, Chron's disease and other conditions is positive, the agency's biosimilars approval pace is "too slow," this PBM says.
Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity is open for pharmacists and pharmacy technicians: "The expanding role of direct oral anticoagulants in the management of thromboembolic disease." Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
FDA staff recently decided that Celltrion and Pfizer's biosimilar (Remsima) to Johnson & Johnson's Remicade for rheumatoid arthritis was "highly similar" to the branded drug. How this will lead to more cost-effective solutions for RA, Chron's disease, and other conditions. Read more
|
|
|
